Wikipedia -WSS

Wikipedia

author：fashion 2025-09-28 01:37:36 - browse：853

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： 10 reasons why health care startups fail

WSS

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Why depression after traumatic brain injury is distinct

Steward Health Care Massachusetts hospitals face fiscal disaster

Medicare drug price negotiation legal challenge met with skepticism

How generative AI ratchets up security threats for health systems

Why you shouldn’t ask, “What country has the best health care?”

hotspot

Wikipedia

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HHS secretary Becerra pressed on Change HealthCare cyberattack

23andMe had bad news about my health. I wish a person had delivered it

Medicare drug price negotiation legal challenge met with skepticism

New air purifier tech could be key to improving indoor air quality

New clues to why women have higher risk of autoimmune disorders

Activists slam private health insurers over coverage restrictions

President Biden's budget: Here's what you might have missed

Continuity nursing helped my family in our darkest PICU moments

Zyn nicotine pouches become unlikely player in latest culture war

explore

Bernie Sanders is gearing up to subpoena pharma CEOs

Health Care Service Corp to buy Cigna Medicare Advantage plans

President Biden's budget: Here's what you might have missed

Biogen walks away from Aduhelm, years after polarizing approval

White House pharmacy plagued with problems, investigation finds

Merck, Johnson & Johnson CEOs will testify on high drug prices

explore

focus

focus

focus